Michael A. Liss, MD, PhD, MAS, FACS, presented “Molecular Testing with Next Generation Sequencing: Role in Urology” during the 33rd International Prostate Cancer Update on January 24, 2023, in Vail, Colorado.
How to cite: Liss, Michael A. “Molecular Testing with Next Generation Sequencing: Role in Urology.” January 2023, 2023. Accessed Nov 2024. https://grandroundsinurology.com/molecular-testing-with-next-generation-sequencing-role-in-urology/
Molecular Testing with Next Generation Sequencing: Role in Urology – Summary
Michael A. Liss, MD, PhD, MAS, FACS, discusses the profound significance of molecular testing with Next-Gen Sequencing (NGS) in the field of urology. With a primary focus on DNA and RNA analysis, NGS facilitates the identification of genetic mutations present in both germline and tumor DNA. This opens up new avenues for understanding the role of environmental factors, genetics, age, and dietary habits in shaping the microbiome and its impact on urological conditions.
He then discusses the potential therapeutic targets that can be identified through NGS. By analyzing the genetic profiles obtained through this advanced sequencing technique, healthcare professionals can pinpoint specific molecular aberrations that can serve as targets for innovative treatment approaches. Additionally, NGS allows for the identification of biomarkers associated with urological diseases, facilitating early detection and more precise monitoring of patients’ conditions.
About The 33rd Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 33rd iteration of the meeting occurred January 22-25, 2023 in Vail, Colorado. To view more educational presentations from IPCU 33, visit our collection page.
ABOUT THE AUTHOR
Michael A. Liss MD, PhD, MAS, FACS is a Urologic Oncologist and Associate Professor at the University of Texas (UT) Health San Antonio. He earned his BS from Benedictine University in Illinois and received his MD from the Medical College of Wisconsin. Dr. Michael Liss completed his residency at the University of California Irvine and then the Society of Urologic Oncology (SUO)-approved Urologic Oncology Fellowship at the University of California San Diego and is a Fellow of the American College of Surgeons. Dr. Liss won Clinical Investigator of the Year 2017 for the UT Health Cancer Center and is also the Director of Clinical Research at UT Health, San Antonio. His surgical skills include robotic and traditional open surgical procedures. His training allows him to be able to choose a patient-specific approach to surgical resection.
Dr. Liss completed a Masters Degree in Applied Science with a focus in Clinical Research to acquire the knowledge to design and implement cutting-edge clinical trials. He was selected as the principal investigator of SWOG (formerly Southwest Oncology Group), which is a partner in the National Cancer Institute’s (NCI’s) National Clinical Trials Network (NCTN). In this capacity, he works with oncologists at UT Health Cancer Center to open the newest clinical trials in San Antonio to include the Veterans Affairs Medical Center. His primary research interests include incorporating imaging and biomarker translational research into interventional clinical trials.
